Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

2026 Is Poised For Even Bigger Gains Than Last Year

View original at finance.yahoo.com
2026 Is Poised For Even Bigger Gains Than Last Year Stocks are off to a mostly good, but uneven start this year. YTD, the Dow is up 2.99%; the S&P is off -0.14%; the Nasdaq is down -2.99%, the small-cap Russell 2000 is up 6.64%; and the mid-cap S&P 400 is up 7.82%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q3 2026 EPS growth is forecast at 11.0%

    80% confidence
  • AI demand is insatiable and AMD alone could grow by 35% a year for the next 3-5 years because of that

    80% confidence
  • The AI market is faster than anything we have seen before

    80% confidence
  • The AI data center market could grow to $1 trillion by 2030

    80% confidence
  • Q2 2026 EPS growth is forecast at 14.1%

    80% confidence
  • The amount of investment in AI will dwarf that of the dot-com era and already has

    80% confidence
  • We are still in the relatively early stages of the transformational AI boom and it has years more to go

    80% confidence
  • We are on the cusp of a small-cap renaissance

    80% confidence
  • PPI wholesale inflation is at 3.0% year-over-year, up from last month's 2.6% but down from last year's high of 3.7%

    80% confidence
  • PCE index came in at 2.8%, down from previous month's 2.9% and below last year's high of 3.0%

    80% confidence
  • Stocks in the top 50% of Zacks Ranked Industries outperform those in the bottom 50% by a factor of 2 to 1

    80% confidence
  • Core CPI inflation is at 2.5% year-over-year, down from 3.3% earlier last year

    80% confidence
  • 2026 will be the fourth consecutive year of double-digit gains for the S&P 500

    80% confidence
  • AI will revolutionize every industry, from healthcare to transportation

    80% confidence
  • The best strategies produced gains up to +98.6% in 2025 while the S&P 500 gained +17.5%

    80% confidence
  • The AI boom could possibly result in 5 or more years of boom times similar to the 1995-1999 dot-com era

    80% confidence
  • Zacks Rank #1 Strong Buy stocks have beaten the market in 29 of the last 38 years with an average annual return of nearly 24%

    80% confidence
  • Q1 2026 EPS growth is forecast at 10.8%

    80% confidence
  • AI is the most powerful technology force of our time

    80% confidence
  • Recent volatility in AI names is nothing more than long overdue profit taking after heady gains

    80% confidence
  • The AI boom is not over and companies investing heavily in AI will see a return

    80% confidence
  • We are at the beginning of a new computing era

    80% confidence
  • Q4 2026 EPS growth is forecast at 13.1%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com